SG10202002612PA - Novel immunotherapy against several tumors, such as lung cancer, including nsclc - Google Patents
Novel immunotherapy against several tumors, such as lung cancer, including nsclcInfo
- Publication number
- SG10202002612PA SG10202002612PA SG10202002612PA SG10202002612PA SG10202002612PA SG 10202002612P A SG10202002612P A SG 10202002612PA SG 10202002612P A SG10202002612P A SG 10202002612PA SG 10202002612P A SG10202002612P A SG 10202002612PA SG 10202002612P A SG10202002612P A SG 10202002612PA
- Authority
- SG
- Singapore
- Prior art keywords
- lung cancer
- against several
- immunotherapy against
- several tumors
- including nsclc
- Prior art date
Links
- 206010058467 Lung neoplasm malignant Diseases 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
- 201000005202 lung cancer Diseases 0.000 title 1
- 208000020816 lung neoplasm Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
- C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24065—Macrophage elastase (3.4.24.65), i.e. metalloelastase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Marine Sciences & Fisheries (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361862213P | 2013-08-05 | 2013-08-05 | |
| GBGB1313987.8A GB201313987D0 (en) | 2013-08-05 | 2013-08-05 | Novel immunotherapy against several tumors, such as lung cancer including NSCLC |
| GBGB1403297.3A GB201403297D0 (en) | 2014-02-25 | 2014-02-25 | Novel immunotherapy against several tumors, such as lung cancer, including NSCLC |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202002612PA true SG10202002612PA (en) | 2020-05-28 |
Family
ID=52460698
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201802399WA SG10201802399WA (en) | 2013-08-05 | 2014-08-04 | Novel immunotherapy against several tumors, such as lung cancer, including nsclc |
| SG10202002608WA SG10202002608WA (en) | 2013-08-05 | 2014-08-04 | Novel immunotherapy against several tumors, such as lung cancer, including nsclc |
| SG11201510580UA SG11201510580UA (en) | 2013-08-05 | 2014-08-04 | Novel immunotherapy against several tumors, such as lung cancer, including nsclc |
| SG10202002612PA SG10202002612PA (en) | 2013-08-05 | 2014-08-04 | Novel immunotherapy against several tumors, such as lung cancer, including nsclc |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201802399WA SG10201802399WA (en) | 2013-08-05 | 2014-08-04 | Novel immunotherapy against several tumors, such as lung cancer, including nsclc |
| SG10202002608WA SG10202002608WA (en) | 2013-08-05 | 2014-08-04 | Novel immunotherapy against several tumors, such as lung cancer, including nsclc |
| SG11201510580UA SG11201510580UA (en) | 2013-08-05 | 2014-08-04 | Novel immunotherapy against several tumors, such as lung cancer, including nsclc |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US20160168200A1 (en) |
| EP (10) | EP3616711A1 (en) |
| JP (1) | JP2016527293A (en) |
| KR (9) | KR102317816B1 (en) |
| CN (1) | CN105377290B (en) |
| AU (10) | AU2014304544B2 (en) |
| BR (1) | BR112016000810A2 (en) |
| CA (4) | CA3073394A1 (en) |
| CL (1) | CL2016000227A1 (en) |
| CR (4) | CR20200139A (en) |
| DK (2) | DK3456339T3 (en) |
| EA (1) | EA035362B1 (en) |
| ES (1) | ES2764406T3 (en) |
| HK (1) | HK1222121A1 (en) |
| HU (1) | HUE047079T2 (en) |
| IL (1) | IL243788B (en) |
| LT (1) | LT3030255T (en) |
| MX (1) | MX2016001426A (en) |
| NZ (2) | NZ714163A (en) |
| PE (3) | PE20160717A1 (en) |
| PH (1) | PH12015502638A1 (en) |
| PL (1) | PL3030255T3 (en) |
| PT (1) | PT3030255T (en) |
| RS (1) | RS59861B1 (en) |
| SG (4) | SG10201802399WA (en) |
| SI (1) | SI3030255T1 (en) |
| TW (10) | TWI777197B (en) |
| UA (1) | UA122661C2 (en) |
| WO (1) | WO2015018805A1 (en) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| PL3456339T3 (en) * | 2013-08-05 | 2022-03-21 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors, such as lung cancer including nsclc |
| CA2935960C (en) | 2014-01-08 | 2023-01-10 | Bart Lipkens | Acoustophoresis device with dual acoustophoretic chamber |
| GB201504502D0 (en) * | 2015-03-17 | 2015-04-29 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers |
| CR20210232A (en) * | 2015-03-17 | 2022-06-24 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers |
| DK3273986T3 (en) | 2015-03-27 | 2024-02-12 | Immatics Biotechnologies Gmbh | PREVIOUSLY UNKNOWN PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNE THERAPY AGAINST DIFFERENT TUMORS |
| GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| GB201505585D0 (en) | 2015-03-31 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers |
| TWI772927B (en) * | 2015-03-31 | 2022-08-01 | 德商英麥提克生物技術股份有限公司 | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (rcc) and other cancers |
| GB201507030D0 (en) * | 2015-04-24 | 2015-06-10 | Immatics Biotechnologies Gmbh | Immunotherapy against lung cancers, in particular NSCLC |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| GB201507719D0 (en) * | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
| JP6985153B2 (en) * | 2015-05-06 | 2021-12-22 | イマティクス バイオテクノロジーズ ゲーエムベーハー | Novel peptides and peptides and their scaffolds for use in immunotherapy for colorectal cancer (CRC) and other cancers |
| TWI751557B (en) * | 2015-06-19 | 2022-01-01 | 德商英麥提克生物技術股份有限公司 | Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer and other cancers |
| MA42294B1 (en) | 2015-07-01 | 2020-11-30 | Immatics Biotechnologies Gmbh | New peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| PT3319985T (en) * | 2015-07-06 | 2021-01-06 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers |
| MY189596A (en) * | 2015-07-15 | 2022-02-18 | Immatics Biotechnologies Gmbh | A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers |
| GB201513921D0 (en) | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| UA125817C2 (en) | 2015-08-28 | 2022-06-15 | Імматікс Біотекнолоджіс Гмбх | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
| US10130693B2 (en) | 2015-08-28 | 2018-11-20 | Immatics Biotechnologies Gmbh | Peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| GB201515321D0 (en) | 2015-08-28 | 2015-10-14 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| GB201517538D0 (en) | 2015-10-05 | 2015-11-18 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
| MY198087A (en) | 2015-10-05 | 2023-07-31 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
| KR20170049024A (en) * | 2015-10-28 | 2017-05-10 | 숙명여자대학교산학협력단 | Composition for prevention or treating cancer comprising inhibitors for expression or activity of ANKs1a, and screening method for thereof |
| GB201521746D0 (en) | 2015-12-10 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers |
| PE20230343A1 (en) | 2015-12-11 | 2023-03-01 | Immatics Biotechnologies Gmbh | PEPTIDES THAT STIMULATE ANTI-TUMORAL IMMUNE RESPONSES |
| US10383896B2 (en) | 2015-12-11 | 2019-08-20 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against various cancers |
| GB201521894D0 (en) | 2015-12-11 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against various cancers |
| KR20180107102A (en) | 2015-12-16 | 2018-10-01 | 그릿스톤 온콜로지, 인코포레이티드 | Identification of new antigens, manufacture, and uses |
| SG10202111399YA (en) * | 2015-12-22 | 2021-11-29 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers |
| GB201522667D0 (en) * | 2015-12-22 | 2016-02-03 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers |
| GB201602918D0 (en) * | 2016-02-19 | 2016-04-06 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
| GB201603987D0 (en) * | 2016-03-08 | 2016-04-20 | Immatics Biotechnologies Gmbh | Uterine cancer treatments |
| GB201604458D0 (en) * | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| BR112018070067A2 (en) * | 2016-04-06 | 2019-02-12 | Immatics Biotechnologies Gmbh | peptides and peptide combinations for use in immunotherapy against lma and other cancers |
| PE20181897A1 (en) * | 2016-04-21 | 2018-12-11 | Immatics Biotechnologies Gmbh | IMMUNOTHERAPY AGAINST MELANOMA AND OTHER TYPES OF CANCER |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| GB201609193D0 (en) | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
| JP7075125B2 (en) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | A novel peptide, peptide combination as a target and for use in immunotherapy for gallbladder cancer and cholangiocarcinoma and other cancers |
| US10868749B2 (en) * | 2016-07-26 | 2020-12-15 | Motorola Mobility Llc | Method and apparatus for discovering neighborhood awareness networking devices based on presence |
| HRP20211677T1 (en) * | 2016-08-17 | 2022-02-18 | Immatics Biotechnologies Gmbh | T cell receptors and immune therapy using the same |
| TWI796299B (en) * | 2016-08-26 | 2023-03-21 | 德商英麥提克生物技術股份有限公司 | Novel peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers |
| US11332530B2 (en) | 2016-09-23 | 2022-05-17 | Memorial Sloan Kettering Cancer Center | Determinants of cancer response to immunotherapy |
| CN110139875B (en) * | 2016-09-30 | 2023-03-03 | 武汉华大吉诺因生物科技有限公司 | COL14A 1-derived tumor antigen polypeptide and application thereof |
| AU2017367696A1 (en) * | 2016-12-01 | 2019-06-20 | Nant Holdings Ip, Llc | Tumor antigenicity processing and presentation |
| DE102016123893A1 (en) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T cell receptors with improved binding |
| EP4317432A3 (en) | 2016-12-08 | 2024-04-17 | Immatics Biotechnologies GmbH | T cell receptors with improved pairing |
| WO2018170313A1 (en) * | 2017-03-16 | 2018-09-20 | Advaxis, Inc. | Methods and compositions for increasing efficacy of vaccines |
| MA49123A (en) * | 2017-04-10 | 2020-03-25 | Immatics Biotechnologies Gmbh | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LEUKEMIA AND OTHER CANCERS |
| EP3628048A4 (en) * | 2017-04-28 | 2021-01-06 | Chung Shan Medical University | Peptides for cancer treatment |
| CA3068852A1 (en) | 2017-07-07 | 2019-01-10 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc, sclc and other cancers |
| WO2019007974A1 (en) | 2017-07-07 | 2019-01-10 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc, sclc and other cancers |
| CN111465989A (en) | 2017-10-10 | 2020-07-28 | 磨石肿瘤生物技术公司 | Identification of neoantigens using hot spots |
| GB201717578D0 (en) * | 2017-10-26 | 2017-12-13 | Univ College Cardiff Consultants Ltd | Novel T-cell receptor |
| EP3714275A4 (en) | 2017-11-22 | 2021-10-27 | Gritstone bio, Inc. | Reducing junction epitope presentation for neoantigens |
| BR112020009889A2 (en) | 2017-12-14 | 2020-11-03 | Flodesign Sonics, Inc. | acoustic transducer driver and controller |
| DE102018107224A1 (en) | 2018-02-21 | 2019-08-22 | Immatics Biotechnologies Gmbh | Peptides and combinations of peptides of non-canonical origin for use in immunotherapy against various cancers |
| TW202016131A (en) * | 2018-05-16 | 2020-05-01 | 德商英麥提克生物技術股份有限公司 | Peptides for use in immunotherapy against cancers |
| KR20210013105A (en) * | 2018-05-23 | 2021-02-03 | 그릿스톤 온콜로지, 인코포레이티드 | Shared antigen |
| CN110627895B (en) * | 2018-06-25 | 2021-03-23 | 北京大学 | Lung cancer specific TCR and analysis technology and application thereof |
| US10925947B2 (en) * | 2018-06-29 | 2021-02-23 | Immatics Biotechnologies Gmbh | A*03 restricted peptides for use in immunotherapy against cancers and related methods |
| CA3135618A1 (en) * | 2019-04-02 | 2020-10-08 | The General Hospital Corporation | Methods to enhance t cell regeneration |
| WO2021016109A1 (en) * | 2019-07-19 | 2021-01-28 | The Regents Of The University Of California | T-cell receptors and methods of use thereof |
| CN111020024A (en) * | 2019-12-05 | 2020-04-17 | 复旦大学附属眼耳鼻喉科医院 | Application of TLR9 |
| CN111808908A (en) * | 2020-06-18 | 2020-10-23 | 华中科技大学同济医学院附属协和医院 | Detection method of gaMSCs subgroup promoting glioma drug resistance |
| CN116583295A (en) * | 2020-12-07 | 2023-08-11 | 印地安纳大学理事会 | Method for sensitizing cancer cells to immune attack using atractylenolide I |
| CN113881707B (en) * | 2021-10-25 | 2023-07-14 | 中国人民解放军军事科学院军事医学研究院 | Product, method and application for regulating and controlling immune suppression effect of umbilical cord mesenchymal stem cells |
| CN113969264B (en) * | 2021-11-29 | 2023-12-08 | 中南大学 | COG5 gene knockout human embryonic stem cell line, construction method and application |
| CN115125203B (en) * | 2022-07-08 | 2023-10-27 | 珠海贝索细胞科学技术有限公司 | Th2 cell in-vitro culture method |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8212000B2 (en) * | 1970-02-11 | 2012-07-03 | Immatics Biotechnologies Gmbh | Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules |
| US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| YU44186B (en) | 1978-12-22 | 1990-04-30 | Biogen Nv | Process for obtaining recombinant dnk molecules |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
| US4897445A (en) | 1986-06-27 | 1990-01-30 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide bond |
| GB2294267B (en) | 1993-06-03 | 1996-11-20 | Therapeutic Antibodies Inc | Anti-TNFalpha Fab fragments derived from polyclonal IgG antibodies |
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| ATE244300T1 (en) | 1996-01-17 | 2003-07-15 | Imp College Innovations Ltd | IMMUNOTHERAPY USING CYTOTOXIC T LYMPHOCYTES (CTL) |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| JP2004503213A (en) | 2000-03-27 | 2004-02-05 | テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド | Single-stranded class I major histocompatibility complex, construct encoding the same and method of producing the same |
| US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
| AU2001275246B2 (en) | 2000-06-05 | 2006-06-29 | Altor Bioscience Corporation | T cell receptor fusions and conjugates and methods of use thereof |
| US7919467B2 (en) * | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| US7087727B2 (en) * | 2001-08-13 | 2006-08-08 | Dana-Farber Cancer Institute, Inc. | Periostin-based diagnostic assays |
| US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| CA2476625A1 (en) | 2002-02-20 | 2003-08-28 | Dyax Corp. | Mhc-peptide complex binding ligands |
| WO2004018633A2 (en) * | 2002-08-20 | 2004-03-04 | The Government Of The United States Of America As Represented By The Secretary, Department Of Healthand Human Services | Abca13 nucleic acids and proteins, and uses thereof |
| WO2004033685A1 (en) | 2002-10-09 | 2004-04-22 | Avidex Ltd | Single chain recombinant t cell receptors |
| DK1558643T3 (en) | 2002-11-09 | 2009-09-07 | Immunocore Ltd | Cell receptor presentation |
| GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| KR100535326B1 (en) * | 2004-01-20 | 2005-12-09 | 한국생명공학연구원 | Differentiation regulating agent containing gene which regulating differentiation from stem cell to natural killer cell as effective ingradient |
| CN102875681A (en) | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | Anti-alpha v beta 6 antibodies and uses thereof |
| ATE461214T1 (en) * | 2005-09-05 | 2010-04-15 | Immatics Biotechnologies Gmbh | TUMOR-ASSOCIATED PEPTIDES THAT BIND TO DIFFERENT CLASS II HUMAN LEUCOCYTE ANTIGENS |
| DE602005016112D1 (en) * | 2005-09-05 | 2009-10-01 | Immatics Biotechnologies Gmbh | Tumor-associated peptides that bind HLA class I or II molecules and anti-tumor vaccines |
| US20090028793A1 (en) * | 2006-02-22 | 2009-01-29 | Philogen Spa | Vascular Tumor Markers |
| US20080107668A1 (en) * | 2006-08-30 | 2008-05-08 | Immunotope, Inc. | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| SI2567707T1 (en) * | 2007-07-27 | 2017-01-31 | Immatics Biotechnologies Gmbh | Composition of tumour-associated peptides and related anti-cancer vaccine |
| WO2009036246A2 (en) * | 2007-09-14 | 2009-03-19 | Immunotope, Inc. | Immunogens that induce cytotoxic t-lymphocytes and their use in prevention, treatment, and diagnosis of cancer |
| WO2009064854A2 (en) | 2007-11-13 | 2009-05-22 | Cogenesys, Inc | Humanized antibodies against tl1a |
| US7996174B2 (en) * | 2007-12-18 | 2011-08-09 | Teradyne, Inc. | Disk drive testing |
| CA2717538A1 (en) * | 2008-03-03 | 2009-09-11 | Dyax Corp. | Metalloproteinase 12 binding proteins |
| WO2009126271A1 (en) * | 2008-04-11 | 2009-10-15 | China Synthetic Rubber Corporation | Methods, agents and kits for the detection of cancer |
| DK2113253T3 (en) | 2008-04-30 | 2010-07-19 | Immatics Biotechnologies Gmbh | New Composition of Tumor-Associated Peptides Binding to Human Leukocyte Antigen (HLA) Class I or II Molecules for Vaccine Use |
| TWI526219B (en) * | 2008-06-19 | 2016-03-21 | 腫瘤療法 科學股份有限公司 | Cdca1 epitope peptides and vaccines containing the same |
| JP5719298B2 (en) * | 2008-08-29 | 2015-05-13 | シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ | Recombinant anti-epidermal growth factor receptor antibody composition |
| DK2172211T3 (en) * | 2008-10-01 | 2015-02-16 | Immatics Biotechnologies Gmbh | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers |
| WO2010045388A2 (en) * | 2008-10-14 | 2010-04-22 | Dyax Corp. | Use of mmp-9 and mmp-12 binding proteins for the treatment and prevention of systemic sclerosis |
| EP2221063A1 (en) * | 2009-02-20 | 2010-08-25 | Ganymed Pharmaceuticals AG | Methods and compositions for diagnosis and treatment of cancer |
| US9310370B2 (en) | 2009-05-15 | 2016-04-12 | Pacific Edge Limited | Markers for detection of gastric cancer |
| US20110033516A1 (en) * | 2009-08-06 | 2011-02-10 | Medical University Of South Carolina | Methods and compositions for bone healing by periostin |
| US8281222B2 (en) | 2009-08-07 | 2012-10-02 | Via Technologies, Inc. | Detection and correction of fuse re-growth in a microprocessor |
| JP2013508409A (en) | 2009-10-23 | 2013-03-07 | トランザイム・ファーマ，インコーポレイテッド | Macrocyclic inhibitors of serine protease enzymes |
| TWI485245B (en) * | 2010-01-25 | 2015-05-21 | Oncotherapy Science Inc | Modified melk peptides and vaccines containing the same |
| KR101378919B1 (en) | 2010-01-28 | 2014-04-14 | 포항공과대학교 산학협력단 | System biological method of biomarker selection for diagnosis of lung cancer, subtype of lung cancer, and biomarker selected by the same |
| GB201004575D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers |
| GB201004551D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| GB201006360D0 (en) * | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| GB201009222D0 (en) * | 2010-06-02 | 2010-07-21 | Immatics Biotechnologies Gmbh | Improved cancer therapy based on tumour associated antigens derived from cyclin D1 |
| CA2816225A1 (en) | 2010-10-26 | 2012-05-03 | Technion Research & Development Foundation Ltd. | Antibodies which bind soluble t-cell receptor ligands |
| US9028810B2 (en) * | 2010-12-20 | 2015-05-12 | Ajou University Industry—Academic Cooperations Foundatin | Composition for inducing migration of neural stem cells containing periostin as effective ingredient |
| WO2013057586A1 (en) | 2011-10-19 | 2013-04-25 | Oslo Universitetssykehus Hf | Compositions and methods for producing soluble t - cell receptors |
| GB201319446D0 (en) * | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
-
2014
- 2014-08-01 TW TW109124801A patent/TWI777197B/en active
- 2014-08-01 TW TW109124798A patent/TWI776192B/en active
- 2014-08-01 TW TW109124803A patent/TWI819228B/en active
- 2014-08-01 TW TW109124799A patent/TWI777196B/en active
- 2014-08-01 TW TW109124796A patent/TWI775117B/en active
- 2014-08-01 TW TW109124795A patent/TWI777194B/en active
- 2014-08-01 TW TW109124802A patent/TWI777198B/en active
- 2014-08-01 TW TW103126327A patent/TWI636065B/en active
- 2014-08-01 TW TW107123070A patent/TWI714869B/en active
- 2014-08-01 TW TW109124797A patent/TWI777195B/en active
- 2014-08-04 RS RS20191676A patent/RS59861B1/en unknown
- 2014-08-04 PL PL14750175T patent/PL3030255T3/en unknown
- 2014-08-04 EP EP19202056.8A patent/EP3616711A1/en active Pending
- 2014-08-04 UA UAA201600268A patent/UA122661C2/en unknown
- 2014-08-04 KR KR1020217001136A patent/KR102317816B1/en active IP Right Grant
- 2014-08-04 KR KR1020187026992A patent/KR102217680B1/en active IP Right Grant
- 2014-08-04 KR KR1020207029963A patent/KR102213554B1/en active IP Right Grant
- 2014-08-04 KR KR1020207029977A patent/KR102213552B1/en active IP Right Grant
- 2014-08-04 EP EP19202064.2A patent/EP3616712A1/en active Pending
- 2014-08-04 CA CA3073394A patent/CA3073394A1/en active Pending
- 2014-08-04 CA CA2912500A patent/CA2912500C/en active Active
- 2014-08-04 AU AU2014304544A patent/AU2014304544B2/en active Active
- 2014-08-04 SG SG10201802399WA patent/SG10201802399WA/en unknown
- 2014-08-04 CA CA3020939A patent/CA3020939C/en active Active
- 2014-08-04 SI SI201431453T patent/SI3030255T1/en unknown
- 2014-08-04 KR KR1020207029978A patent/KR102213551B1/en active IP Right Grant
- 2014-08-04 PE PE2015002616A patent/PE20160717A1/en active Application Revival
- 2014-08-04 EP EP19202010.5A patent/EP3616707A1/en active Pending
- 2014-08-04 WO PCT/EP2014/066755 patent/WO2015018805A1/en active Application Filing
- 2014-08-04 ES ES14750175T patent/ES2764406T3/en active Active
- 2014-08-04 EP EP19202000.6A patent/EP3613427A1/en active Pending
- 2014-08-04 EP EP18201334.2A patent/EP3456339B1/en active Active
- 2014-08-04 EP EP19171543.2A patent/EP3578196A1/en active Pending
- 2014-08-04 SG SG10202002608WA patent/SG10202002608WA/en unknown
- 2014-08-04 EP EP19202037.8A patent/EP3616709A1/en active Pending
- 2014-08-04 DK DK18201334.2T patent/DK3456339T3/en active
- 2014-08-04 EP EP19202028.7A patent/EP3616708A1/en active Pending
- 2014-08-04 PE PE2020000409A patent/PE20201284A1/en unknown
- 2014-08-04 CR CR20200139A patent/CR20200139A/en unknown
- 2014-08-04 KR KR1020167000976A patent/KR102098329B1/en active IP Right Grant
- 2014-08-04 KR KR1020187026995A patent/KR102098327B1/en active IP Right Grant
- 2014-08-04 MX MX2016001426A patent/MX2016001426A/en unknown
- 2014-08-04 EP EP14750175.3A patent/EP3030255B1/en active Active
- 2014-08-04 CN CN201480035925.8A patent/CN105377290B/en active Active
- 2014-08-04 NZ NZ714163A patent/NZ714163A/en unknown
- 2014-08-04 HU HUE14750175A patent/HUE047079T2/en unknown
- 2014-08-04 EA EA201690016A patent/EA035362B1/en unknown
- 2014-08-04 BR BR112016000810A patent/BR112016000810A2/en not_active Application Discontinuation
- 2014-08-04 NZ NZ733168A patent/NZ733168A/en unknown
- 2014-08-04 LT LTEP14750175.3T patent/LT3030255T/en unknown
- 2014-08-04 SG SG11201510580UA patent/SG11201510580UA/en unknown
- 2014-08-04 KR KR1020207029965A patent/KR102213556B1/en active IP Right Grant
- 2014-08-04 US US14/908,078 patent/US20160168200A1/en not_active Abandoned
- 2014-08-04 CR CR20180508A patent/CR20180508A/en unknown
- 2014-08-04 EP EP19202046.9A patent/EP3616710A1/en active Pending
- 2014-08-04 PT PT147501753T patent/PT3030255T/en unknown
- 2014-08-04 SG SG10202002612PA patent/SG10202002612PA/en unknown
- 2014-08-04 KR KR1020207018007A patent/KR102211542B1/en active IP Right Grant
- 2014-08-04 JP JP2016532350A patent/JP2016527293A/en active Pending
- 2014-08-04 DK DK14750175.3T patent/DK3030255T3/en active
- 2014-08-04 PE PE2018001559A patent/PE20181538A1/en unknown
- 2014-08-04 CR CR20210464A patent/CR20210464A/en unknown
- 2014-08-04 CA CA3073256A patent/CA3073256A1/en active Pending
-
2015
- 2015-11-26 PH PH12015502638A patent/PH12015502638A1/en unknown
-
2016
- 2016-01-08 CR CR20160018A patent/CR20160018A/en unknown
- 2016-01-26 IL IL24378816A patent/IL243788B/en active IP Right Grant
- 2016-01-28 CL CL2016000227A patent/CL2016000227A1/en unknown
- 2016-08-30 HK HK16110313.1A patent/HK1222121A1/en unknown
- 2016-11-21 US US15/357,838 patent/US10071148B2/en active Active
-
2017
- 2017-06-30 US US15/639,058 patent/US9943579B2/en active Active
-
2018
- 2018-01-17 AU AU2018200389A patent/AU2018200389B2/en active Active
-
2020
- 2020-08-17 AU AU2020220039A patent/AU2020220039B2/en active Active
- 2020-08-17 AU AU2020220041A patent/AU2020220041B2/en active Active
- 2020-08-17 AU AU2020220038A patent/AU2020220038B2/en not_active Ceased
- 2020-08-17 AU AU2020220042A patent/AU2020220042B2/en active Active
- 2020-08-17 AU AU2020220040A patent/AU2020220040B2/en active Active
- 2020-08-17 AU AU2020220044A patent/AU2020220044B2/en active Active
- 2020-08-17 AU AU2020220045A patent/AU2020220045B2/en active Active
- 2020-08-17 AU AU2020220043A patent/AU2020220043B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1222121A1 (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc ( nsclc ) | |
| IL280565A (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
| GB201507030D0 (en) | Immunotherapy against lung cancers, in particular NSCLC | |
| EP2971284A4 (en) | Subtyping lung cancers | |
| EP2968254A4 (en) | Methods of treating lung cancer | |
| GB201322725D0 (en) | Cancer therapy | |
| HK1220900A1 (en) | Cancer therapy | |
| EP2994148B8 (en) | Cancer therapy | |
| EP3007756A4 (en) | Catheter-assisted tumor treatment | |
| EP3044593A4 (en) | Cancer therapy | |
| EP2961412A4 (en) | Cancer therapy | |
| EP3015476A4 (en) | Tumor biomarker | |
| EP3277325A4 (en) | Combination immunotherapy for small cell lung cancer | |
| IL245477A0 (en) | Lung cancer diagnosis | |
| GB201313987D0 (en) | Novel immunotherapy against several tumors, such as lung cancer including NSCLC | |
| GB201403297D0 (en) | Novel immunotherapy against several tumors, such as lung cancer, including NSCLC | |
| EP3077812A4 (en) | Methods for the prognosis of breast cancer | |
| GB201317213D0 (en) | Cancer Therapy |